The FDA approved a once-monthly olanzapine injection for schizophrenia
On October 9 the FDA approved Teva's Weltruza, a long-acting injection for adults with schizophrenia. Teva expects a U.S. launch within weeks. It is not a cure.
Read the original
The reporting lives at CNBC. Our summary is checked against it, and we link it on every story.
On October 9, 2026, the Food and Drug Administration approved Weltruza, Teva's once-monthly injection of olanzapine, for adults with schizophrenia. CNBC reported that Teva expects to launch it in the United States within weeks. Olanzapine is an antipsychotic that patients have taken for years as a daily pill. Weltruza is a long-acting form of that drug, given once a month, which could make consistent treatment easier than a pill every day.
The approval means the FDA has allowed the product to be marketed for adults with this illness. It is not a cure, and it is not approved here for children. CNBC's report confirms the approval, the monthly schedule, and the launch window. It does not say how many people were in the studies, how much symptoms changed, or how long patients were followed, so this summary does not claim a specific size of benefit. The injection is not in pharmacies yet. Weltruza is the second U.S. product from Teva's partnership with Medincell, after Uzedy, a long-acting form of risperidone that the FDA approved in 2023.
More good news
Other stories in the same neighborhood of kindness.
Health & TechFDA approved an oral pill for herpes lesions that resist standard drugs in people with weak immune systems
Hovilpri (pritelivir) is for immunocompromised adults whose lesions did not respond to acyclovir, valacyclovir, or famciclovir. The trial was open-label, and herpes still has no cure.
Verified · U.S. Food and Drug Administration
Health & TechAdding atezolizumab cut the risk of stage III dMMR colon cancer returning
In a 712-patient trial, adding atezolizumab to chemotherapy after surgery halved the risk of the cancer returning or of death. Median disease-free survival was not reached, and overall survival was not the result reported.
Verified · U.S. Food and Drug Administration
Health & TechAdding tucatinib lengthened the time before HER2-positive breast cancer progressed
In a 654-person maintenance trial, median progression-free survival was 24.9 months with tucatinib and 16.3 months with placebo. Overall survival is not known yet.
Verified · U.S. Food and Drug Administration